# Scribe Therapeutics

engineered CasX (X-edit) CRISPR platform, partnered with Sanofi on in-vivo editing.


Source: https://en.bioecon.ru/companies/scribe-therapeutics/
Updated: 2026-07-29

- Country: United States

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Funding | $128.7 million IPO (July 2026) and ~$150 million raised prior to IPO | https://endpoints.news/gene-editor-scribe-starts-second-half-ipo-spree-with-129m-listing/, https://medcitynews.com/2026/07/scribe-therapeutics-ipo-crispr-genetic-medicine-pcsk9-ascvd-sctx/, https://www.sec.gov/Archives/edgar/data/1853921/000119312526294804/d21355ds1.htm |
| Funding | Grant funding from CIRM of up to ~$25.7 million | https://medcitynews.com/2026/07/scribe-therapeutics-ipo-crispr-genetic-medicine-pcsk9-ascvd-sctx/, https://www.biospace.com/scribe-therapeutics-announces-research-collaboration-with-sanofi-to-accelerate-breakthrough-crispr-based-cell-therapies-for-cancer, https://www.scribetx.com/newsroom/scribe-therapeutics-awarded-more-than-25-million-from-cirm-to-accelerate-additional-crispr-based-gene-editing-therapies-for-cardiometabolic-disease-into-clinical-trials, https://www.sec.gov/Archives/edgar/data/1853921/000119312526294804/d21355ds1.htm |
| Headcount | 88-89 employees as of mid-2026 | https://stockanalysis.com/stocks/sctx/employees/ |
| Headquarters | 1150 Marina Village Parkway, Alameda, CA 94501, United States | https://medcitynews.com/2026/07/scribe-therapeutics-ipo-crispr-genetic-medicine-pcsk9-ascvd-sctx/, https://www.sec.gov/Archives/edgar/data/1853921/000119312526294804/d21355ds1.htm, https://www.sec.gov/Archives/edgar/data/1853921/000119312526308330/d21355dex1013.htm |
| Regulatory approval | Australian TGA clearance for STX-1150 Phase 1 clinical trial (May 2026) | https://medcitynews.com/2026/07/scribe-therapeutics-ipo-crispr-genetic-medicine-pcsk9-ascvd-sctx/, https://www.sec.gov/Archives/edgar/data/1853921/000119312526294804/d21355ds1.htm |
| Partnership | Strategic collaborations with Sanofi (in vivo and ex vivo) and Eli Lilly (neurological/neuromuscular) | https://www.biospace.com/scribe-therapeutics-announces-research-collaboration-with-sanofi-to-accelerate-breakthrough-crispr-based-cell-therapies-for-cancer, https://www.sec.gov/Archives/edgar/data/1853921/000119312526294804/d21355ds1.htm, https://www.sec.gov/Archives/edgar/data/1853921/000119312526308330/d21355dex1013.htm |
| Production site | Uses third-party contract manufacturing organizations (CMOs) | https://www.sec.gov/Archives/edgar/data/1853921/000119312526294804/d21355ds1.htm, https://www.sec.gov/Archives/edgar/data/1853921/000119312526308330/d21355dex1013.htm |

Independent sources: biospace.com, endpoints.news, medcitynews.com, scribetx.com, sec.gov, stockanalysis.com

## Technologies

- [Genome editing](https://en.bioecon.ru/technology/genome-editing/)